Intestinal hyperpermeability — “leaky gut” — occurs when tight junctions between intestinal epithelial cells break down, allowing bacterial endotoxins, undigested food antigens, and microbial products to enter the bloodstream and trigger systemic inflammation. This underlies or worsens dozens of conditions including autoimmunity, brain fog, food sensitivities, skin disorders, and metabolic disease. Peptide research directly targets tight junction repair and mucosal regeneration.
1. BPC-157 — Tight Junction Repair / Mucosal Healing
BPC-157 is the most studied peptide for intestinal barrier repair. It directly upregulates tight junction proteins (occludin, claudin, ZO-1), promotes angiogenesis in gut mucosa, and dramatically accelerates healing of the intestinal lining. Multiple animal studies show complete reversal of intestinal permeability with BPC-157 administration.
Dosing Protocol: 500 mcg oral BPC-157 (arginate form) daily, taken on an empty stomach. For combined systemic and local effects, stack with 250 mcg SubQ daily. Cycle: 8–12 weeks minimum.
2. KPV — Intestinal Anti-Inflammatory
KPV (Lys-Pro-Val) specifically targets NF-κB inflammatory signaling in intestinal epithelial cells and immune cells in the gut mucosa. It reduces the pro-inflammatory cytokine storm (IL-6, IL-8, TNF-α) that damages tight junctions and perpetuates mucosal inflammation — directly addressing the inflammatory driver of permeability.
Dosing Protocol: 200–500 mcg oral (in capsule, best for gut targeting) or SubQ daily. Oral preferred for intestinal permeability. Cycle: 6–8 weeks.
3. VIP — Gut Motility / Immune Tolerance
Vasoactive Intestinal Peptide (VIP) plays a key physiological role in gut mucosal immune tolerance and motility regulation. In leaky gut, immune tolerance in the gut-associated lymphoid tissue (GALT) is impaired. VIP restores secretory IgA production, promotes regulatory immune responses in the gut, and supports mucosal healing.
Dosing Protocol: 25–50 mcg SubQ or intranasal daily. Can be administered via enema for targeted lower GI effects. Cycle: 4–6 weeks.
4. Thymosin Alpha-1 — Gut Immune Normalization
The gut is the largest immune organ, and in leaky gut, immune dysregulation perpetuates barrier damage. Thymosin Alpha-1 normalizes gut-associated immune function — reducing the Th17-driven inflammation attacking the mucosal barrier while promoting Treg-mediated tolerance to luminal antigens.
Dosing Protocol: 1.5 mg SubQ twice weekly. Cycle: 8 weeks. Best used after BPC-157 has begun repairing the physical barrier.
BPC-157 is the cornerstone — directly rebuilding the tight junction proteins that constitute the physical barrier. KPV quiets the intestinal inflammatory environment that keeps destroying that barrier. VIP restores the mucosal immune tolerance needed for long-term gut homeostasis, and Thymosin Alpha-1 normalizes the systemic immune dysregulation that often originates from, and feeds back into, the leaky gut cycle.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).